

Suggested Reading – Key Articles

Endometrial Cancer

1. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2004; 22: 3902-8.
2. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 22: 2159-66, 2004.
3. Randall M, Filiaci V, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 24:36-44, 2006.
4. Thigpen, T., Brady, M., Alvarez, R., Adelson, M., Homesby, H., Monelta, A., Soper, J. and Given, F. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group. *J. Clin. Oncol.* 17: 1736-1744, 1999.
5. Aaron H. Wolfson, Mark F. Brady, Thomas Rocereto, et al: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. *Gynecol Oncol* 107: 177-185, 2007.
6. Howard D. Homesley, Virginia Filiaci, Maurie Markman, et al: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. *J Clin Oncol* 25:526-531, 2007.
7. Hensley M, Blessing J, Mannel R and Rose P: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase III trial. *Gynecol Oncol* 109: 329-34, 2008.